These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26198336)

  • 1. Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?
    Cho EJ; Lee JH; Yoon JH
    Gut Liver; 2016 Jul; 10(4):497-8. PubMed ID: 26198336
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting treatment outcomes for HBV patients.
    AIDS Patient Care STDS; 2009 Mar; 23(3):223. PubMed ID: 19480059
    [No Abstract]   [Full Text] [Related]  

  • 3. The royal wedding in chronic hepatitis B: The haves and the have-nots for the combination of pegylated interferon and nucleos(t)ide therapy.
    Lampertico P
    Hepatology; 2015 May; 61(5):1459-61. PubMed ID: 25645624
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.
    Shi Y; Wu YH; Shu ZY; Zhang WJ; Yang J; Chen Z
    Hepatobiliary Pancreat Dis Int; 2010 Oct; 9(5):462-72. PubMed ID: 20943454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.
    Jansen L; Kootstra NA; van Dort KA; Takkenberg RB; Reesink HW; Zaaijer HL
    J Infect Dis; 2016 Jan; 213(2):224-32. PubMed ID: 26216905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
    Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
    J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of efficacy of pegylated interferon alfa-2a or interferon alfa-2b combination therapy with nucleus(t)ide analogues in HBeAg positive chronic hepatitis B patients].
    Wang SQ; Xu KJ; Wu JZ; Liu XS; Luo TT; Yang RG; Geng XX; Huang RG; Lin JM; Jiang N
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):785-6. PubMed ID: 22423366
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interferon therapy for chronic hepatitis B].
    Tang WL; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):726-9. PubMed ID: 19874685
    [No Abstract]   [Full Text] [Related]  

  • 9. [Interferon therapy for hepatitis B and C].
    Iino S
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():559-63. PubMed ID: 17455681
    [No Abstract]   [Full Text] [Related]  

  • 10. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).
    Brouwer WP; Xie Q; Sonneveld MJ; Zhang N; Zhang Q; Tabak F; Streinu-Cercel A; Wang JY; Idilman R; Reesink HW; Diculescu M; Simon K; Voiculescu M; Akdogan M; Mazur W; Reijnders JG; Verhey E; Hansen BE; Janssen HL;
    Hepatology; 2015 May; 61(5):1512-22. PubMed ID: 25348661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B.
    Kaymakoglu S; Oguz D; Gur G; Gurel S; Tankurt E; Ersöz G; Ozenirler S; Kalayci C; Poturoglu S; Cakaloglu Y; Okten A
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3020-2. PubMed ID: 17517832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
    Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
    J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK; Lai LS; Lam P; Zhang HY; Fung TT; Lai ST; Wong WM; Lo CM; Fan ST; Leung N; Lau GK;
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1171-8. PubMed ID: 16611278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
    Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B.
    Papadopoulos V; Protopapas A; Tsianos E; Mimidis K
    Scand J Gastroenterol; 2009; 44(8):1021-2. PubMed ID: 19424932
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.